Study	Reason for exclusion
Abali 2007	non‐randomised study
Adamo 1994	antiblastic therapy used as treatment regimen
Albany 2014	non‐randomised study
Audhuy 1996	application of dexamethasone has not been reported
Ballatori 1995	dexamethasone has been used in only 1 arm
Barrajon 2000	cost‐benefit analysis
Belle 2002	no use of 5‐hydroxytryptamine‐3 (5‐HT₃) receptor antagonists in first 2 arms, along with neurokinin‐1 (NK₁) receptor antagonist
Bianchi 1996	application of dexamethasone has not been reported
Bonneterre 1994	a letter
Bonneterre 1995	application of dexamethasone has not been reported
Bubalo 2001	application of dexamethasone has not been reported
Bubalo 2012	objectives of this article are (1) to assess the pharmacokinetics of aprepitant in cancer patients undergoing HSCT, and (2) to examine the potential drug–drug interaction between aprepitant and cyclophosphamide
Campora 1994	application of dexamethasone has not been reported
Chiou 2000	chemotherapy regimen is not clearly reported
Choi 2014	non‐randomised study
Cocquyt 2001	use of 5‐hydroxytryptamine‐3 (5‐HT₃) receptor antagonist has been reported in only 1 arm
Craver 2011	non‐randomised study
Creed 1999	no information given regarding randomisation, no comparator against ondansetron
Dandamudi 2011	docetaxel belongs to low emetogenic chemotherapy regimen
Dong 2011	dexamethasone was permitted as rescue medication
Fauser 1995	application of dexamethasone has not been reported
Fauser 1996	application of dexamethasone has not been reported
Fauser 1999	dexamethasone has been used in only 1 arm
Fedele 1995	correspondence
Feng 2000	application of dexamethasone has not been reported
Feng 2002	application of dexamethasone has not been reported
Fengyi 2002	application of dexamethasone has not been reported
Gebbia 1994	application of dexamethasone has not been reported
Goldschmidt 1997	no use of dexamethasone reported
Gralla 1998	application of dexamethasone has not been reported
Gralla 2003	application of dexamethasone has not been reported
Hesketh 1996	application of dexamethasone has not been reported
Huang 1998	comparison of identical dose of Zudan and Zofran; both are ondansetron
Huang 2001	no information available regarding randomisation
Huang 2013	application of dexamethasone has not been reported
Huc 1998	application of dexamethasone has not been reported
Hudis 2003	retrospective subset analysis
Humphreys 2013	cost‐effectiveness study
Iihara 2012	application of dexamethasone has not been reported
Italian Group for Antiemetic Research 1993	use of metoclopramide in 1 arm
Italian Group for Antiemetic Research 1995 (a)	on Days 2 to 4 after chemotherapy, all patients received oral metoclopramide + intramuscular dexamethasone as antiemetic prophylaxis for delayed emesis
Italian Group for Antiemetic Research 1995 (b)	use of metoclopramide
Jantunen 1993	application of dexamethasone has not been reported
Kang 2002	application of dexamethasone has not been reported
Kawaguchi 2015	concurrent chemoradiotherapy
Kilickap 2013	chemotherapy regimen is not clearly reported
Kim 1998	application of dexamethasone has not been reported
Kim 2004	application of dexamethasone has not been reported
Kim 2012	detailed chemotherapy regimens within the HEC group have not been reported
Lacerda 2000	addition of lorazepam in all treatment arms
Lavoie 2012	use of 5‐hydroxytryptamine‐3 (5‐HT₃) receptor antagonist has not been reported
Lee 2014	chemotherapy regimen is not clearly mentioned
Leonardi 1996	application of dexamethasone has not been reported
Lindley 2005	comparison of ondansetron, prochlorperazine, and dexamethasone in 3 individual arms
Lofters 1995	dolasetron (dol) vs ondansetron (ond) with and without dexamethasone (dex) to evaluate additive effects of i.v. DEX with each drug
Long 2002	no information available regarding randomisation
Loos 2007	pharmacokinetic study
Mandanas 2005	addition of lorazepam in all treatment arms
Martoni 1996	application of dexamethasone has not been reported
Marty 1995	application of dexamethasone has not been reported
Matsui 1996	patients were randomly assigned to receive granisetron alone (arm 1) or granisetron, dexamethasone, and prochlorperazine (arm 2)
Matsuoka 2003	treatment arms include granisetron + dexamethasone vs granisetron alone
Meiri 2007	efficacy determination of dronabinol alone and in combination with ondansetron vs ondansetron alone
Micha 2016	application of dexamethasone has not been reported in Cycle 1
Molassiotis 2013	study type: pooled analysis of different trials
Monda 1994	no information given regarding randomisation
Moore 2007	cost‐effectiveness study
Nasu 2013	application of dexamethasone has not been reported
Navari 2016	review
NCT04636632	comparison of different preparations of the same drug
Nishimura 2015 (a)	5‐HT₃ not defined and use of both fosaprepitant and aprepitant in 1 group reported
Nishimura 2015 (b)	5‐HT₃ not defined and use of both fosaprepitant and aprepitant in 1 group reported
Noble 1994	application of dexamethasone has not been reported
Noda 2002	application of dexamethasone has not been reported
Öge 2000	application of dexamethasone has not been reported
Ogihara 1999	dexamethasone has been reported in only 1 group
Ohta 1992	ondansetron or saline injection has been given to patients
Ottoboni 2014	pharmacokinetic and dose‐finding study
Park 1997	application of dexamethasone has not been reported
Pater 1997	non‐randomised study
Pectasides 2007	application of dexamethasone has not been reported
Perez 1996	no information given regarding randomisation
Perez 1998 (a)	application of dexamethasone has not been reported
Perez 1998 (b)	dexamethasone or methylprednisolone was permitted as a prophylactic component of pre‐therapy
Peterson 1996	dexamethasone has been reported in only 1 group
Plasencia‐Mota 1993	no information given regarding randomisation
Poon 1998	application of dexamethasone has not been reported
Qiu 2011	application of dexamethasone has not been reported
Roila 2009	dose‐finding study
Roscoe 2012	no individual data have been provided for HEC and MEC regimens
Ruff 1994	application of dexamethasone has not been reported
Ruhlmann 2016	5 weeks of fractionated radiotherapy and concomitant weekly cisplatin have been used
Rzepecki 2009	non‐randomised study; historical control group
Saito 2015	chemotherapy regimen is not clearly reported
Sheng 2010	application of dexamethasone and chemotherapy regimen have not been reported
Shi 2007	application of dexamethasone has not been reported
Silvestris 2013	a letter
Slabý 2000	application of dexamethasone has not been reported
Spector 1998	application of dexamethasone has not been reported
Stewart 1995	application of dexamethasone has not been reported
Sun 2014	application of dexamethasone has not been reported
Suzuki 2015	pharmacogenomics study
Takenaka 2007	no information given regarding randomisation
Takeshima 2014	non‐randomised study and no comparator has been used
Tan 2004	no individual data have been provided for HEC and MEC regimens
Tang 2013	application of dexamethasone has not been reported
Tanimura 1998	dose‐finding study
Tian 2011	application of dexamethasone has not been reported
Tominaga 1996	application of dexamethasone has not been reported
Tong 2012	concurrent radiochemotherapy
Tong 2014	application of dexamethasone and chemotherapy regimen have not been reported
Tremont‐Lukats 2017	application of dexamethasone has not been reported
Tsavaris 1996	application of dexamethasone has not been reported
Tsubata 2015	no use of dexamethasone has been reported
Tsuji 2016	pharmacogenomics study
Tsukuda 1995	application of dexamethasone has not been reported
Uchino 2012	retrospective study
Vadhan‐Raj 2011	pharmacological study
Vadhan‐Raj 2012	pharmacological study
Vadhan‐Raj 2014	pharmacological study
Vadhan‐Raj 2015	pharmacological study
Van Belle 2002	no use of 5‐hydroxytryptamine‐3 (5‐HT₃) receptor antagonist has been reported in 2 of 3 arms
Van der Vorst 2021	metoclopramide used as part of the antiemetic regimen
Walko 2012	pharmacological study
Weant 2017	application of dexamethasone has not been reported
Xie 2003	use of dexamethasone has not been reported
Yahata 2016 (a)	no clear distinction in presenting results for granisetron and ondansetron
Yalçin 1999	application of dexamethasone has not been reported
Yang 2005	application of dexamethasone has not been reported
Yano 2005	application of dexamethasone has not been reported
Yu 2009	application of dexamethasone has not been reported
Zeidman 1998	non‐randomised study
Zeng 2001	application of dexamethasone and chemotherapy regimen have not been reported
Zhang 1996	application of dexamethasone has not been reported
Zhang 1999	application of dexamethasone has not been reported
Zhang 2002	phase 1, pharmacokinetic study
Zhang 2003	use of dexamethasone has not been reported
Zhang 2003 (a)	application of dexamethasone has not been reported
Zhang 2007	application of dexamethasone has not been reported
Zhang 2012	phase 1, pharmacokinetic study